-
The internationalization of Chinese medicine has entered the "fast lane", and these problems need to be resolved urgently
Time of Update: 2021-10-22
The industry believes that these products have accelerated and successfully launched in overseas markets, marking a key breakthrough in the internationalization of Chinese medicine, and Chinese medicine companies have entered the international market .
-
A new target for tumor immunity!
Time of Update: 2021-10-22
Preclinical studies have shown that SIM0235 has high binding specificity, can effectively block the activation of NF-κB signaling pathway induced by the combination of tumor necrosis factor α (TNFα) and TNFR2, effectively inhibit the proliferation and function of Treg cells, and regulate the immune microenvironment .
-
Drug Administration: Kangye Medical Devices and Zhongyi Technology are recalling a batch of medical devices
Time of Update: 2021-10-22
On September 27, the State Food and Drug Administration issued an announcement to notify Kangye Medical Devices and Zhongyi Technology of the voluntary recall of some of its products in violation of regulations .
-
Bojian was sued by insurance company Humana for illegally promoting drug sales through charitable donations
Time of Update: 2021-10-22
Biogen is also one of the pharmaceutical companies that previously signed a settlement agreement with the US government, but now the medical insurance giant Humana is filing a new lawsuit against the company's illegal charitable donations .
-
Amgen's lipid-lowering drug Repatha receives FDA approval to treat children with HeFH cholesterol disease
Time of Update: 2021-10-22
CompilationFan DongdongA few days ago, the FDA announced that it would approve the use of Amgen’s PCSK9 inhibitor Repatha as an additional treatment for dietary adjustments and statins for the treatment of pediatric patients 10 years of age and older with heterozygous familial hypercholesterolemia (HeFH).
-
Hengrui Medicine's 1.3 billion innovative drug Punaburin will be another wealth code?
Time of Update: 2021-10-22
Figure 2 The inhibitory activity of punabulin on tumor cell lines and drug-resistant tumor cell linesIn 2011, Professor Hayashi summarized the structure-activity relationship of punabrine modified by phenylahistin (see Figure 3): 1.
-
Ruike Biotechnology and Ruiji Biotechnology reached an mRNA vaccine cooperation agreement
Time of Update: 2021-10-22
The joint venture company will use mRNA technology and new adjuvant technology to develop a new generation of new crown vaccines, and plans to gradually expand to other major infectious disease vaccines and tumor therapeutic vaccines .
-
Centralized procurement to promote insulin and Chinese patent medicines to promote drug bidding in one place and publish new "retaliatory" regulations
Time of Update: 2021-10-22
Looking back at the first round of the first-round list of 20 key monitored drugs issued by the National Health and Medical Commission, they did not include proprietary Chinese medicines .
On September 25th, Hubei issued an announcement on the centralized procurement of the Inter-Provincial Volume Procurement Alliance of Chinese Patent Medicines .
-
Luye Pharma's Class 1 new drug, a new generation of VMAT2 inhibitor LY03015, will soon enter the clinic in China
Time of Update: 2021-10-22
In addition to products already on the market, Luye Pharma has a number of new drugs under development that have entered the late-stage clinical and New Drug Application (NDA) stages in China, the United States and other markets, covering a variety of diseases such as depression and Parkinson's disease, forming in the central nervous system treatment field.
-
Andorra's third-generation oral breast cancer Class 1 new drug was approved for clinical use in the U.S.
Time of Update: 2021-10-22
On October 1, the third-generation oral breast cancer class 1 new drug AND019 independently developed by Andorra Pharmaceuticals obtained clinical approval from the US FDA .
-
Unannounced inspections for drug retail companies Shunyi
Time of Update: 2021-10-22
Recently, the Shunyi District Market Supervision Administration continued to carry out unannounced inspections of pharmaceutical retail companies throughout the district, continuously strengthened the supervision of pharmaceutical retail companies, and urged pharmacies to play the role of "sentinel" to ensure the quality and safety of pharmaceutical equipment in the jurisdiction .
-
Summary and outlook of the pharmaceutical equipment industry in the first three quarters of 2021
Time of Update: 2021-10-22
The industry believes that or indirectly brings development opportunities to the upstream pharmaceutical equipment industry; another example is Chinese medicine formula granules.
Favorable policy advancement, entering the fourth quarter, the pharmaceutical equipment industry is expected to continue its growth trend .
-
Eisai China won the 2020 Economic Contribution Award-Outstanding Contribution Award for Output Efficiency
Time of Update: 2021-10-22
Suzhou, October 8, 2021/PRNewswire/ - On September 28, Eisai China won the 2020 Economic Contribution in the 2021 Suzhou Municipal Government’s exchange activities with multinational companies and the awarding ceremony of the honorary title of Suzhou’s foreigners Award-Outstanding Contribution Award for Output Benefits, in recognition of the remarkable, iconic and leading contribution to Suzhou's economic development .
-
Many places began to implement the fifth batch of national sourcing of medicines, and a new competition pattern in the pharmaceutical market is approaching
Time of Update: 2021-10-22
It is reported that the fifth batch of national procurement of medicines has a total of 61 products selected, with an average decrease of 56%; the varieties involve common diseases such as hypertension, diabetes, coronary heart disease, digestive tract diseases, and drugs for chronic diseases, as well as drugs for major diseases such as lung cancer and pancreatic cancer.
-
In the third quarter, cell therapy and gene editing were frequently favored by capital
Time of Update: 2021-10-22
For example, on July 30 this year, the newly established Xingyiang Biotech announced the completion of a US$40 million angel round of financing led by Eli Lilly Asia Fund.
-
The domestic pharmaceutical machinery industry is ushering in a new period of development opportunities, and two major problems need to be resolved urgently
Time of Update: 2021-10-22
In addition, under the "three-child concept", the demand for children's drugs may also grow further, and the production capacity of related pharmaceutical companies is expected to usher in a new round of expansion and upgrade, and this impact may also indirectly affect the upstream pharmaceutical equipment industry.
-
With the continuous expansion of the market size of Chinese herbal medicine decoction pieces, ensuring high-quality development has become a top priority
Time of Update: 2021-10-22
. Industry analysis believes that, in fact, in recent years, market regulatory authorities in various regions have been constantly "strikes out", strengthened special rectification of traditional Chinese medicine decoction pieces, actively promoted standardized production, strengthened supervision of pesticide residues, and regulated the operation and use behavior of traditional Chinese medicine decoction pieces.
-
Hengrui wins the first review with 2 billion anesthetics
Time of Update: 2021-10-22
Author: Bai YuA few days ago, Hengrui Pharmaceuticals issued an announcement stating that the company has been approved for inhalation sevoflurane for imitation of the 4 types of applications and is deemed to have been reviewed.
-
Domestically-made innovative drugs are speeding up overseas, and many new drugs are about to be launched abroad
Time of Update: 2021-10-22
S. Food and Drug Administration (FDA) has also accepted Baiyueze® for the treatment of marginal zone lymphoma (MZL) adults who have previously received at least one CD20-directed therapy The patient’s New Indication Marketing Application (sNDA) and granted priority review qualifications .
-
Weijian Pharmaceuticals and China Rare Disease Alliance strategically cooperate to help the construction of a healthy ecology for rare diseases
Time of Update: 2021-10-22
Boao, Hainan, October 8, 2021/PRNewswire/ - September 30, 2021 (Hainan·Boao), Hong Kong Weijian Pharmaceutical Group ("Vaijian Pharmaceutical") and China Rare Disease Alliance formally signed a five-y
